Natera, Inc. (NASDAQ:NTRA) CEO Sells $960,038.10 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 6,111 shares of Natera stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $157.10, for a total value of $960,038.10. Following the completion of the transaction, the chief executive officer now owns 179,071 shares in the company, valued at approximately $28,132,054.10. This represents a 3.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Thursday, May 1st, Steven Leonard Chapman sold 6,980 shares of Natera stock. The stock was sold at an average price of $150.10, for a total transaction of $1,047,698.00.
• On Monday, April 28th, Steven Leonard Chapman sold 6,203 shares of Natera stock. The shares were sold at an average price of $152.18, for a total value of $943,972.54.
• On Monday, April 21st, Steven Leonard Chapman sold 1,664 shares of Natera stock. The stock was sold at an average price of $145.55, for a total value of $242,195.20.
• On Monday, March 31st, Steven Leonard Chapman sold 9,563 shares of Natera stock. The stock was sold at an average price of $138.41, for a total value of $1,323,614.83.
• On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The shares were sold at an average price of $146.03, for a total value of $978,693.06.

Natera Stock Performance

Shares of NTRA stock traded up $7.07 during midday trading on Wednesday, hitting $167.22. The company had a trading volume of 1,334,039 shares, compared to its average volume of 1,406,394. The company's 50 day simple moving average is $150.83 and its 200 day simple moving average is $158.58. Natera, Inc. has a 52-week low of $92.14 and a 52-week high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market cap of $22.83 billion, a price-to-earnings ratio of -95.01 and a beta of 1.79.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. During the same quarter in the previous year, the company earned ($0.56) EPS. The company's quarterly revenue was up 36.5% on a year-over-year basis. Research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on NTRA. UBS Group raised their price target on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Canaccord Genuity Group restated a "buy" rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Royal Bank of Canada initiated coverage on Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target on the stock. Barclays boosted their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Finally, Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and a consensus price target of $184.63.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Natera by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company's stock worth $1,752,611,000 after buying an additional 77,357 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares during the last quarter. JPMorgan Chase & Co. increased its position in Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after purchasing an additional 660,538 shares during the last quarter. Wellington Management Group LLP increased its position in Natera by 15.7% during the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after purchasing an additional 439,778 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Natera by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after buying an additional 142,201 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.